



BRIAN SANDOVAL
Governor

STATE OF NEVADA
DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 E. William Street, Suite 101
Carson City, Nevada 89701
(775) 684-3600

RICHARD WHITLEY
Director

LAURIE SQUARTSOFF
Administrator

Division of Health Care Financing and Policy
Notice of meeting to solicit public comments and intent to act
Upon Amendments to the Medicaid Services Manual (MSM)

Public Hearing June 11, 2015
Minutes

Date and Time of Meeting: June 11, 2015 at 9:00 am

Name of Organization: State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP)

Place of Meeting: State of Nevada Health Division
4150 Technology Way, Room 303
Carson City, Nevada 89706

Place of Video Conference: The Division of Health Care Financing and Policy (DHCFP)
1210 S. Valley View Blvd. Suite 104
Las Vegas, Nevada 89102

Attendees

In Carson City, NV

Carl Jeffery, Catamaran
Jennie Bonk, DHCFP
Jennifer Shaffer, HPES
Kathy Stoner, DHCFP
Jessica Vannucci, DHCFP
Tammy Moffitt, DHCFP
Adam Pan, Ferrari Public Affairs
Marti Cote', DHCFP

Adrienne Navarro, DHCFP
Denise Stokich, DHCFP
Robin Landry, DHCFP
Sarah Ramirez, HPES
Betsy Aiello, DHCFP
Darrell Faircloth, Senior DAG
Theresa Carsten, DHCFP
Chris Bosse, Renown Health

In Las Vegas, NV

Janet Belcove-Shalin, NDALC
Lisa D'Asunta, UMC
Karen Bullen, DHCFP

Renee Nemchek, UMC
Victor Guerrero, DHCFP

Introduction:

Ms. Tammy Moffitt, Chief of Program Integrity, Division of Health Care Financing and Policy (DHCFP), opened the Public Hearing introducing herself, Ms. Betsy Aiello, Deputy Administrator of the DHCFP and Mr. Darrell Faircloth, Senior Deputy Attorney General (DAG).

Ms. Moffitt – The notice for this public hearing was published on May 11, 2015 in accordance with the Nevada Revised Statute 422.2369.

1. Discussion of proposed changes to MSM Chapter 600 - Physician Services

Ms. Jenni Bonk:

Revisions to MSM Chapter 600 are being proposed to remove Attachments B, C, D, E, F, G and H from the chapter. These attachments are medical consent, acknowledgment and certification statement forms. They do not contain any policy information. These forms are being relocated to the DHCFP website at <http://www.dhcfp.nv.gov> under Forms and the Hewlett Packard Enterprise Services (HPES) provider portal at <http://www.medicaid.nv.gov/providers/forms/forms.aspx>. Any references made to these forms within the chapter have been updated to direct providers to the correct internet sites.

The effective date is June 12, 2015.

At the conclusion of Ms. Bonk's presentation, Ms. Moffitt asked Ms. Aiello, Deputy Administrator, and Mr. Faircloth, DAG, if they had any questions or comments.

Ms. Aiello's Comments:

- No Comments

Mr. Faircloth's Comments:

- Please confirm there is no policy information in the forms and all the limitations on the services that were ensconced within these forms are found within the chapter and remain in the chapter. The forms are now being published on the Internet and reside there to be more readily accessed.
- Ms. Bonk responded yes, that is correct.

Public Comments:

- No Comments

Ms. Moffitt– Recommended the Deputy Administrator approve as submitted.

Ms. Aiello – Approved as submitted.

Ms. Moffitt– Closed the Public Hearing for the MSM Chapter 600 - Physician Services.

2. For Possible Action: Discussion and Proposed Adoption of the Nevada Medicaid Hysterectomy Acknowledgement Form

Ms. Jenni Bonk:

This form is being removed from MSM Chapter 600, Physician Services. Providers will now be able to obtain the Acknowledgement Receipt of Hysterectomy Information Form (Pre-, Post- and Emergency) on the DHCFP's website at <http://dhcftp.nv.gov> and on HPES website at <http://www.medicaid.nv.gov/providers/forms/forms.aspx>. Providers are not required to use this specific form as long as they have an equivalent Acknowledgment Receipt of Hysterectomy Information (After Surgery) form completed and on file for submission and reimbursement of claims.

The effective date is July 1, 2015.

At the conclusion of Ms. Bonk's presentation, Ms. Moffitt asked Ms. Aiello, Deputy Administrator, and Mr. Faircloth, DAG, if they had any questions or comments.

Ms. Aiello's Comments:

- No Comments

Mr. Faircloth's Comments:

- No Comments

Public Comments:

- No Comments

Ms. Moffitt – Recommended the Deputy Administrator approve as submitted.

Ms. Aiello – Approved as submitted.

Ms. Moffitt– Closed the Public Hearing on the Nevada Medicaid Hysterectomy Acknowledgement Form.

3. For Possible Action: Discussion and Proposed Adoption of the Personal Care Services (PCS) Functional Assessment and Service Plan (FASP) Form.

Ms. Adrienne Navarro:

The PCS FASP form and instructions have been updated to provide clarifying language in the form instructions for the ratings of the Activities of Daily Living (ADL) and the Instrumental Activities of Daily Living (IADL), correct a calculation in the form for the IADL of shopping, from 90 minutes per week to 120 minutes per week for a score of 3, remove "Days per Week" and "Visits per Day" boxes from the form to align with flexibility of services in the PCS program and to add a "Quick Reference Guide" for the maximum time for all ADL and IADL tasks to the instructions.

The effective date is July 1, 2015.

At the conclusion of Ms. Navarro's presentation, Ms. Moffitt asked Ms. Aiello, Deputy Administrator, and Mr. Faircloth, DAG, if they had any questions or comments.

Ms. Aiello's Comments:

- No Comments

Mr. Faircloth's Comments:

- No Comments

Public Comments:

- No Comments

Ms. Moffitt– Recommended the Deputy Administrator approve as submitted.

Ms. Aiello – Approved as submitted.

Ms. Moffitt– Closed the Public Hearing for the Personal Care Services (PCS) Functional Assessment and Service Plan (FASP) Form.

4. For Possible Action: Discussion and proposed adoption of changes to MSM Chapter 100 – Medicaid Program

Ms. Kathy Stoner:

Revisions to MSM Chapter 100 are being proposed to remove language related to the specific number of days in which a facility must initiate an admission and concurrent authorization review process for a recipient who has been discharged from a facility and Medicaid eligibility has been approved retroactively, and for those still in the facility on the date Medicaid eligibility is determined. Reference is made to the provider Billing Manual for the specific timeframe requirements. The provider Billing Manual will increase the timeframe a facility has to initiate the authorization review process for recipients still in a facility when eligibility is determined to allow ten business days instead of the current five days.

The effective date is July 1, 2015.

At the conclusion of Ms. Stoner's presentation, Ms. Moffitt asked Ms. Aiello, Deputy Administrator, and Mr. Faircloth, DAG, if they had any questions or comments.

Ms. Aiello's Comments:

- For clarification, the only change being made is increasing the days to initiate the authorization review process from five business days to ten business days.
- Ms. Stoner responded yes, that is correct.

Mr. Faircloth's Comments:

- No Comments

Public Comments:

- No Comments

Ms. Moffitt– Recommended the Deputy Administrator approve as submitted.

Ms. Aiello – Approved as submitted.

Ms. Moffitt– Closed the Public Hearing for MSM Chapter 100 – Medicaid Program.

5. For Possible Action: Discussion and proposed adoption of changes to MSM Chapter 1200 – Prescribed Drugs

Ms Stoner:

The Drug Use Review (DUR) Board is a requirement of the Social Security Act to identify and reduce fraud, abuse, overuse, and medically unnecessary care. The DUR Board also works to minimize drug interactions, drug-induced illness, and undesirable drug reactions in recipients.

Revised and new prior authorization criteria were approved by the DUR Board on January 22, 2015. Prior authorization criteria were revised for Olysio® (simeprevir), Thrombin Inhibitors (Eliquis®, apixaban; Pradaxa®, dabigatran etexilate; Xarelto®, rivaroxaban), immunomodulator drugs (Entyvio®, vedolizumab), transdermal Fentanyl, and Sovaldi® (sofosbuvir). New prior authorization criteria was established for Harvoni® (ledipasvir-sofosbuvir), and Xartemis® XR (oxycodone and acetaminophen).

The effective date is July 1, 2015.

At the conclusion of Ms. Stoner's presentation, Ms. Moffitt asked Ms. Aiello, Deputy Administrator, and Mr. Faircloth, DAG, if they had any questions or comments.

Ms. Aiello's Comments:

- No Comments

Mr. Faircloth's Comments:

- Appendix A page 17 a change made to prior authorizations for the Transdermal Fentanyl patches that prior approval be given now for a 12 month period, why is this change being made, is it permissible under the pharmacy act.
- Mr. Carl Jeffries, Catamaran, responded Transdermal Fentanyl patches are used for several months or years at a time. Clinical practice makes it very appropriate to treat a patient for 12 months or longer with this medication. Yes, it is permissible under the pharmacy act to extend the prior authorization to 12 months.

Public Comments:

- Mr. Adam Pan from Ferrari Public Affairs stated as a form issue on Appendix A page 16, Section F you are proposing to strike the reference to Duragesic® (fentanyl transdermal) and replace it with Transdermal Fentanyl. on Appendix A page 16, Section F.1.d 1-12 Duragesic

language carries throughout. I believe it would be more appropriate to change each of those references from Duragesie to Transdermal Fentanyl, to be more in line with the other changes proposed.

- Mr. Jeffries responded I would concur; it would make sense to keep it consistent to reference the Transdermal Fentanyl rather than the brand name Duragesie which is another form of Transdermal Fentanyl.
- Ms. Aiello inquired to Mr. Jeffries it is not a policy change, rather changing a name brand to a generic statement, is that correct.
- Mr. Jeffries responded, yes that is correct. There is one manufacture for Duragesis brand and several manufactures for Transdermal Fentanyl, now that there is generic available.

Ms. Moffitt– Recommended the Deputy Administrator approved with the corrections discussed.

Ms. Aiello – Approved with the following changes:

- Appendix A page 16 section F.1 strike the word "two" to read Therefore, patients must meet the following criteria in order to gain prior authorization approval.
- Appendix A page 16 section F.1.d 1-12 change the word "Duragesic" to "Transdermal Fentanyl".
- Appendix A page 23 Section L.1.a 5-7 Remove line through the word "for".
- Appendix A page 55 section HH change the date from April 24, 2014 to January 22, 2015.
- Appendix A page 76 section VV change the date from April 24, 2014 to January 22, 2015.

Ms. Moffitt– Closed the Public Hearing for the Medicaid Services Manual Chapter 1200 - Prescribed Drugs.

6. For Possible Action: Discussion and proposed adoption of changes to MSM Chapter 1300 – DME, Disposable Supplies and Supplements

Ms. Jessica Vannucci:

Revisions to Medicaid Services Manual (MSM) Chapter 1300 are being proposed to update timeframes for Continuous Positive Airway Pressure device (CPAP) and Bi-level Positive Airway Pressure device (Bi-PAP) that were changed to match Medicare's timeframes and expanded sleep study requirements to include titrate and diagnostic. Definition added for misuse and specific items were added to reflect which are non-covered by Nevada Medicaid.

The effective date is July 1, 2015.

At the conclusion of Ms. Vannucci's presentation, Ms. Moffitt asked Ms. Aiello, Deputy Administrator, and Mr. Faircloth, DAG, if they had any questions or comments.

Ms. Aiello's Comments:

- No Comments

Mr. Faircloth's Comments:

- No Comments

Public Comments:

- No Comments

Ms. Moffitt– Recommended the Deputy Administrator approve as submitted.

Ms. Aiello – Approved as submitted.

Ms. Moffitt– Closed the Public Hearing for the Medicaid Services Manual Chapter 1300 - DME, disposable Supplies and Supplements.

7. General Public Comments

- No Comments

8. Adjournment

There were no further comments and Ms. Moffitt adjourned the public hearing at 10:20 AM.

**An Audio (CD) version of this meeting is available through the DHCFP Administration office. For more detailed information on any of the handouts, submittals, testimony and or comments please contact Robyn Heddy at Robyn.Heddy@dncfp.nv.gov or (775) 684-3678 with any questions.*